The Pfizer-BioNTech trial included 44,060 subjects equally distributed into two groups: one that received Dose 1 of either the BNT162b2 mRNA jab from the companies, or a "placebo control" containing 0.9 percent saline.
At Week 20 of the trial, the BNT162b2 mRNA jab illegitimately received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA), which disregarded the safety and effectiveness of ivermectin, as one example, and proceeded to rush its EUA for the Pfizer-BioNTech jab at warp speed.
Once that EUA was issued, trial subjects who were given the "placebo" were offered the BNT162b2 injection. Most of them accepted, save for a few objectors, and Pfizer-BioNTech proceeded to report that the number of deaths in vaccinated versus placebo group during the first 20 weeks showed "no significant difference."